• Placement of Entitlement Offer Shortfall to raise ~A$2.7M
• Aggregate amount raised under Entitlement Offer totals ~A$8.5M
• New funding strengthens balance sheet and provides flexibility for ongoing clinical development and commercialization of NUZ-001

Neurizon Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF), a clinical-stage biotech company focused on developing treatments for neurodegenerative diseases, has received firm commitments to raise A$2,657,000 through the placement of the shortfall from its recently completed pro rata non-renounceable entitlement offer. The Entitlement Offer, announced on 23 December 2025, sought to raise up to approximately A$17.1 million, but closed on 21 January 2026 raising approximately A$5.9 million, resulting in a shortfall of ~A$11.3 million. The new funding, raised through the placement of the Entitlement Offer Shortfall, will further strengthen the company's balance sheet and provide additional financial flexibility to advance the clinical development and commercialization initiatives associated with its lead asset, NUZ-001, as well as for working capital purposes, potentially reducing the need to draw down on the convertible note facility. Neurizon remains focused on disciplined execution across its clinical, regulatory, and corporate priorities as it advances NUZ-001 through Phase 2/3 clinical development and towards near-term milestones.

Neurizon remains focused on disciplined execution across its clinical, regulatory, and corporate priorities as it advances NUZ-001 through Phase 2/3 clinical development and towards near-term milestones.